Virtual Posters

Big Data

PO-001  ARNTL2 is a hypoxia-responsive master regulator of PDAC malignancy. Alvaro Curiel-Garcia¹, Carlo H. Maurer², Pasquale Laise³, Irina Sagalovskiy⁴, John A. Chabot⁴, Gulam A. Manji⁴, Alina Iuga⁵, Kristen Johnson⁶, Andrea Califano⁴, Kenneth P. Olive⁴.
¹Columbia University, New York, NY, ²Technische Universität München, Munich, Germany, ³Darwin Therapeutics, New York, NY, ⁴Columbia University, New York, NY, ⁵University of North Carolina, Chapel Hill, NC, ⁶University of New Hampshire, Manchester, NH.

PO-002  Initial retrospective analysis of mechanisms of FOLFIRINOX resistance using clinical and molecular data from the Know Your Tumor (KYT) pancreatic ductal adenocarcinoma (PDAC) cohort. James M. Davison¹, Greg Mayhew¹, Kirk Beebe¹, Joel R. Eisner¹, Dennis Ladnier², Eric A. Collisson³, Lynn M. Matrisian². ¹GeneCentric Therapeutics, Inc, Durham, NC, ²Pancancer Action Network, Manhattan Beach, CA, ³Division of Hematology and Oncology, Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.

PO-003  Predictors for 30-day readmission in patients with pancreatic cancer who had DNR code status. Jasmeet Kaur¹, Tanveer Mir², Paramveer Singh³, Judie Goodman¹. ¹Saint Joseph Mercy Oakland Hospital, PONTIAC, MI, ²Wayne State University, Detroit, MI, ³Karmanos Cancer Center, Detroit, MI.

PO-004  Basal-like, Classical A, and Classical B subtypes of pancreatic cancer show distinct immuno-suppressive molecular profiles. Emily L. LaPlante¹, Dongliang Liu¹, Aleksandar Milosavljevic¹, Qizhi Yao¹. ¹Baylor College of Medicine, Houston, TX.

PO-005  Proteome profiling of Pancreatic Ductal Adenocarcinoma (PDAC) primary tumors in Caucasian, African Americans and Latinx patients. Henry C. H. Law¹, Andrea N. Riner², Jose G. Trevino³, Nicholas T. Woods¹. ¹University of Nebraska Medical Center, Omaha, NE, ²University of Florida, Gainesville, FL, ³Virginia Commonwealth University, Richmond, VA.

Diagnostics, Early Detection, and Imaging

PO-006  CircRTN4 promotes pancreatic cancer progression through a novel circRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein. Chi Hin Wong¹, Ut Kei Lou¹, Frederic Khe-Cheong Fung¹, Joanna H. M. Tong², Ka-Fai To², Stephen Lam Chan³, Yangchao Chen⁴. ¹School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁴School of Biomedical Sciences, Faculty of Medicine, and Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
PO-007  Plasma-based detection of pancreatic cancer: A multiomics approach. Teng-Kuei Hsu, Tzu-Yu Liu, Billie Gould, Christine Decapite, Amer Zureikat, Alessandro Paniccia, Eric Ariazi, Marvin Bertin, Richard Bourgon, Kaitlyn Coil, Hayley Donnella, Adam Drake, Julie M. Granka, Preet Kaur, Maggie C. Louie, Amit Pasupathy, Ofer Shapira, Peter Ulz, Chun Yang, C. Jimmy Lin, Randall Brand. 1Freenome Holdings Inc., South San Francisco, CA, 2Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 3Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.

PO-008  Diagnostic accuracy of blood-based multi-omic biomarkers for pancreatic adenocarcinoma: A systematic review and meta-analysis. Laura E. Kane, Gregory S. Mellotte, Eimear Mylod, Rebecca O'Brien, Fiona O'Connell, Khanh Nguyen, Croí E. Buckley, Jennifer Arlow, David Mockler, Aidan D. Meade, Barbara M. Ryan, Stephen G. Maher. 1Trinity College Dublin, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Ireland, 3Technological University Dublin, Dublin, Ireland.

PO-009  Multi-omic profiling of patient pancreatic cyst fluid for the identification of a novel biomarker panel of patient cancer risk. Laura E. Kane, Gregory S. Mellotte, Simone Marcone, Barbara M. Ryan, Stephen G. Maher. 1Trinity College Dublin, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Ireland.

PO-010  Detection of early tissue changes on historical CT scans in the regions of the pancreas gland that subsequently develop adenocarcinoma using quantitative textural analysis and fat fraction analysis. Ronald L. Korn, Daniel D. Von Hoff, Andre Burkett, Dominic Zygarldo, Taylor Brodie, Kathleen Panak, Sweta Rajan, Derek Cridebring, Michael J. Demeure. 1Imaging Endpoints, Scottsdale, AZ, 2Translational Genomics Research Institute, Phoenix, AZ, 3Hoag Hospital, Newport Beach, CA.

PO-011  The spectrum of pathogenic germline variants in pancreatic cancer patients with multiple primary tumors. Valentyna Kryklya, Lodewijk A.A. Brosens, Marjolijn J.L. Ligtengberg, Iris D. Nagtegaal. 1Radboud university medical center, Nijmegen, Netherlands, 2University Medical Center Utrecht, Utrecht, Netherlands.

PO-012  The concept of artificial intelligence against pancreatic cancer. Subash Kumar. 1DMI Lochbridge, Elkridge, MD.

PO-014  VISTA: VISual Semantic Tissue Analysis for pancreatic disease quantification in murine cohorts. Luke Ternes1, Ge Huang1, Christian Lanciult1, Guillaume Thibault1, Rachelle Riggers2, Joe Gray2, John Muschler1, Young Hwan Chang1. 1Oregon Health and Science University, Portland, OR, 2Oregon Health and Science University, Portland, OR.

Early Phase Clinical Trials

PO-015  A phase Ib/II trial of high dose ascorbic acid (AA) + paclitaxel protein bound (PP) + cisplatin (C) + gemcitabine (G) in patients (pts) with previously untreated metastatic pancreatic cancer (MPC). Gayle S. Jameson1, Erkut H. Borazanci1, Daniel D. Von Hoff2, Joshua D. Rabinowitz3, Michael S. Gordon1, Sarah D. LeGrand1, Courtney Snyder1, Karen Ansaldo1. 1HonorHealth, Scottsdale, AZ, 2Translational Genomics Research Institute (TGen), Phoenix, AZ, 3Princeton University, Princeton, NJ.

Immunotherapy

PO-016  Directed evolution generates novel oncolytic H-1 parvoviruses with improved therapeutic efficacy in virus-resistant pancreatic cancer cells. Pierre Garcin1, Monireh Kazemimanesh1, Hubert Lulka1, Nelson Dusetti2, Guillaume Labrousse1, Emilie Benuzzi1, Louis Buscail3, Pierre Cordelier1. 1Cancer Research Center of Toulouse, INSERM, Toulouse, France, 2Cancer Research Center of Marseilles, INSERM, Marseilles, France, 3Cancer Research Center of Toulouse, INSERM and Toulouse University Hospital, Toulouse, France.

PO-017  Application of oncolytic adenovirus to desmoplastic pancreatic cancer. Elora Hossain1, Fumihiro Higashino1. 1Hokkaido University, Sapporo, Japan.

PO-019  Reprogramming of naïve B cells in pancreatic cancer subverts humoral immunity. Bhalchandra Mirlekar¹, Yuliya Pylayeva-Gupta¹. ¹Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.

PO-020  Heating up immune cold pancreatic adenocarcinoma with bioengineered immunotherapy remodels tumor microenvironment and prevents metastasis in vivo. Chanthirika Ragulan¹, Patrick Varun Lawrence¹, Hari PS¹, Krishna Desai¹, Jun Ishihara², Anguraj Sadanandam¹. ¹The Institute of Cancer Research, Sutton, United Kingdom, ²Imperial College London, London, United Kingdom.

Metabolism

PO-021  Targeting the mitochondrial pyruvate complex to alter metabolic programming in pancreatic cancer. Hassan A. Ali¹, Andrew Metcalfe², James T. Topham², Cassia S. Warren², Joanna M. Karasinska², David F. Schaeffer², Daniel J. Renouf³. ¹University of British Columbia, Vancouver, BC, Canada, ²Pancreas Centre BC, Vancouver, BC, Canada.

PO-022  Exploiting a redox bottleneck to combat drug tolerance in pancreatic cancer. Holly Brunton¹, Ludimila Cavalcante², David Sumptom¹, Francis Giles², Owen Sansom¹. ¹CRUK Beatson Institute, Glasgow, United Kingdom, ²Actuate Therapeutics, Fort Worth, TX.

PO-023  Impaired adipose anabolism drives fat wasting in pancreatic cancer cachexia. Katherine Pelz¹, Grace McCarthy¹, Heike Mendez¹, Samantha Z. Brown¹, Jonathan R. Brody¹, Aaron J. Grossberg¹. ¹Oregon Health & Science University, Portland, OR.

PO-024  Targeting cellular metabolism with CPI-613 sensitizes pancreatic cancer cells to radiotherapy. William A. Hall¹, Husain Y. Khan², Mandana Kamgar¹, Susan Tsai¹, Kathleen Christians¹, Douglas B. Evans¹, Philip Philip², Callisia Clarke¹, Ben George¹, Beth Erickson¹, Asfar S. Azmi². ¹Medical College of Wisconsin, Milwaukee, WI, ²Karmanos Cancer Institute, Wayne State University, Detroit, MI.


PO-026  CircMYOF acts as a miR-4739 sponge to promote progression and facilitate glycolysis via VEGFA/PI3K/AKT pathway in pancreatic ductal adenocarcinoma. Dandan Zheng¹, Xianxian Huang², Juanfei Peng¹, Yanyan Zhaung¹, Yuanhua Li³, Junchi Qu¹, Shineng Zhang¹, Fengting Huang¹. ¹Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, ²the Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China, ³Tungwah Hospital of Sun Yat-sen University, Dongguan, China.

PO-028 Pancreatic ductal adenocarcinoma is dependent on an unconventional pathway for polyamine synthesis. Nada Y Kalaany. Boston Children's Hospital, Harvard Medical School, Boston, MA.

PO-029 Pancreatic cancer-associated cachexia as a 3-stage systemic disease with changes in body composition, tissue-specific wasting across time and alterations in glucose metabolism. Blanca Majem1, Insia Naqvi1, Courtney Dennis2, Lucas Dailey2, Clary B. Clish2, Nada Kalaany1. 1Boston Children's Hospital, Harvard Medical School, Boston, MA, 2Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA.

PO-030 No time to rest: Vulnerabilities associated with metabolic deprivation in pancreatic cancer cells. Yogev Sela1, Jinyang Li1, Shivahamy Maheswaran1, Robert Norgard1, Salina Yuan1, Maimon Hubbi1, Clementina Measaros1, Ian Blair1, Ophir Shalem1, Chi Van Dang2, Ben Stanger1. 1University of Pennsylvania, Philadelphia, PA, 2Wistar, Philadelphia, PA.

PO-031 Lysosome inhibition overcomes resistance to CDK4/6 inhibition in PDA. Dilru Silva, Conan Kinsey, Martin McMahon. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.

PO-032 Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth. Lifeng Yang, Joshua Rabinowitz. Princeton University, Princeton, NJ.

Microbiome

PO-033 Bacterial cytotoxin therapy limits tumor growth for pancreatic ductal adenocarcinoma. Amanda R. Decker1, Tetsuhiro Harimoto2, Steve A. Sastra1, Tal Danino2, Kenneth P. Olive1. 1Columbia University Medical Center, New York, NY, 2Columbia University, New York, NY.

Other

PO-034 CPSF3 inhibition halts pancreatic cancer cell proliferation by limiting core histone supplies. Abdulrahman A. Alahmari1, Carla Schwarz2, Emily Paterson2, Swati Venkat2, Arwen Tisdale2, Michael E. Feigin2. 1Roswell Park Comprehensive Cancer Center, Amherst, NY, 2Roswell Park Comprehensive Cancer Center, Buffalo, NY.

PO-035 Uncovering a myosin phosphatase regulator in pancreatic tumor cell mechanics and behavior. Shantel M. Angstadt, Qingfeng Zhu, Douglas N. Robinson, Elizabeth M. Jaffee, Robert A. Anders. Johns Hopkins University School of Medicine, Baltimore, MD.

PO-036 LP184, a novel alkylating agent, is highly effective in pancreatic cancers with DNA damage repair defects. Diana Restifo1, Aditya Kulkarni2, Caleb Schimke2, Joseph McDermott2, Umesh Kathad2, Kishor Bhatia2, Panna Sharma2, Igor Aytasov1. 1Fox Chase Cancer Center, Philadelphia, PA, 2Lantern Pharma, Dallas, TX.
PO-037 Development of an RGD CRISPR-modified *Clostridium novyi* NT Spores as an Intravenous Oncotherapy. Kaitlin M. Dailey¹, Krysten Vance², Kyle McAndrews³, Reed I. Jacobson⁴, Jandro Delgado⁵, Paige R. Johnson⁶, Taylor M. Woolery⁵, Megan Orr⁶, Jiha Kim⁷, Sanku Mallik⁵, Kenneth W. Bayles⁸, Michael A. Hollingsworth², Amanda E. Brooks⁹. ¹Eppley Institute for Cancer Research, University of Nebraska Medical Center, and Cell and Molecular Biology Program, Pharmaceutical Sciences Department, North Dakota State University, Omaha, NE, ²Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE, ³Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, Omaha, NE, ⁴Department of Biological Sciences, North Dakota State University, Fargo, ND, ⁵Cell and Molecular Biology Program, Pharmaceutical Sciences Department, North Dakota State University, Fargo, ND, ⁶Department of Statistics, North Dakota State University, Fargo, ND, ⁷Cell and Molecular Biology Program, Pharmaceutical Sciences Department and Department of Biological Sciences, North Dakota State University, Fargo, ND, ⁸Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ⁹Cell and Molecular Biology Program, Pharmaceutical Sciences Department, North Dakota State University, Fargo, ND and Department of Research and Scholarly Activity, Rocky Vista University, Ivins, UT, Fargo, ND.

PO-038 LAMC2: new player in stemness and tumor progression in pancreatic cancer. Donatella Delle Cave¹, Tea Teresa Iavazzo¹, Maria Mangini², Gennaro Andolfi¹, Teresa Pirozzi¹, Annalisa Di Domenico¹, Annachiara De Luca², Enza Lonardo¹. ¹Institute of Genetics and Biophysics ‘Adriano Buzzati-Traverso’ (IGB), CNR, Naples, Italy, ²Institute of Biochemistry and Cellular Biology, National Research Council of Italy, Naples, Italy.

PO-039 Antiproliferative activity of inhibitors of RAD51, singly and in combination with chemotherapy drugs, against pancreatic cancer cell lines. Peter Ferguson¹, Mark D. Vincent¹, Yousef Najajreh², Brian Shilton³, Stephen Ritter³, Rima Al-awar⁴, Richard Marcellus⁴, Mohammed Mohammed⁴, Methvin Isaac⁵, James Koropatnick⁴, ¹London Health Sciences Centre, London, ON, Canada, ²Al Quds University, Jerusalem, Palestinian Territory, ³Western University, London, ON, Canada, ⁴Ontario Institute for Cancer Research, Toronto, ON, Canada.

PO-040 Nischarin is expressed in pancreatic ductal adenocarcinoma and is a potential target for drug repurposing. Jelena Grahovac¹, Marijana Pavlovic¹, Marija Ostojic¹, Kristina Zivic¹, Daniel Galun², Tatjana Srdic-Rajic¹. ¹Institute for Oncology and Radiology of Serbia, Belgrade, Serbia, ²School of Medicine, University of Belgrade; First Surgical Clinic, Clinical Center of Serbia, Belgrade, Serbia.

PO-041 Systemic screening of gene delivery methods in pancreatic ductal adenocarcinoma cells. Dmytro Grygoryev¹, Taelor Ekstrom¹, Jason M. Link², Rosalie C. Sears², Jungsun Kim¹. ¹Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Portland, OR, ²Oregon Health & Science University, Portland, OR.

PO-042 ANGPTL4 accelerates KRAS⁴G12D-induced acinar to ductal metaplasia and
pancreatic carcinogenesis Kyung Hee Jung¹, Young-Chan Youn¹, Soon-Sun Hong¹. ¹College of Medicine, Inha University, Incheon, Republic of Korea.

**PO-043** Cytidine deaminase protects pancreatic cancer cells from replicative stress and drive response to DNA-targeting drugs. Audrey Lumeau¹, Nicolas Bery¹, Cyril Ribeyre², Samad Elkaoutari³, Guillaume Labrousse¹, Miguel Madrid-Mencia¹, Vera Pancaldi¹, Marie-Jeanne Pillaire⁴, Valérie Bergoglio⁵, Nelson Dusseti³, Jean-Sébastien Hoffmann⁶, Louis Buscail⁷, Malik Lutzmann², Pierre Cordelier¹. ¹Cancer Research Center of Toulouse, Toulouse, France, ²IGH Montpellier, Montpellier, France, ³Cancer Research Center of Marseille, Marseille, France, ⁴IPBS Toulouse, Toulouse, France, ⁵CBI Toulouse, Toulouse, France, ⁶IUCT Oncopole Toulouse, Toulouse, France, ⁷CHU Rangueil Toulouse, Toulouse, France.


**PO-045** Targeting HNF1A-dependent stemness and tumor growth in pancreatic ductal adenocarcinoma using BET inhibitors. Bharani Muppavarapu, Ethan Abel, Melanie Mayberry. Roswell Park Comprehensive Cancer Center, Buffalo, NY.

**PO-046** The effect of neoadjuvant therapy on immune profiling of pancreatic ductal adenocarcinoma: a prospective study of the PREOPANC-1 randomized controlled trial. Diba Latifi, Willem de Koning, Sai ping Lau, Frederiek Grevers, Coen van Dam, Casper H. J. van Eijck, Dana A. M. Mustafa. Erasmus University Medical Center, Rotterdam, Netherlands.

**PO-047** Optimizing the efficacy of 5-FU as a chemotherapeutic agent in advanced pancreatic ductal adenocarcinoma (PDAC) using MIAPaCa-2 and PANC-1 cells. Nkafu Bechem Ndemazie¹, Andriana Inkoom¹, Xue Y. Zhu¹, Edward Agyare¹. ¹Florida A&M University, Tallahassee, FL.

**PO-048** A novel chromatin remodeling domain of keratin 17 regulates transcription and promotes tumor aggression in pancreatic cancer. Chun-Hao Pan¹, Robert Tseng¹, Simon J. Hogg², Gabriella Baraks¹, Cindy V. Leiton¹, Lucia Roa-Peña¹, Natalia Marchenko¹, Kenneth R. Shroyer¹, Luisa F. Escobar-Hoyos³. ¹Stony Brook University, Stony Brook, NY, ²Memorial Sloan Kettering Cancer Center, New York, NY, ³Yale University, New Haven, CT.

**PO-049** Inhibiting MNK kinases promotes macrophage immunosuppressive phenotype to limit anti-tumor immunity. Thao ND Pham¹, Christina Spaulding¹, Mario A. Shields¹, Mahmoud G. Khalafalla¹, Daniel R. Principe², David J. Bentrem¹, Hidayatullah G. Munshi¹. ¹Feinberg School of Medicine, Northwestern University, Chicago, IL, ²Medical Scientist Training Program, College of Medicine, University of Illinois at Chicago, Chicago, IL.

**PO-050** Precision Promise (PrP): An adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC). Vincent J. Picozzi¹, Anne-Marie Duliege², Anirban Maitra³, Manuel Hidalgo⁴, Andrew Eugene Hendifar³, Gregory L. Beatty⁶, Sudheer Doss Doss², Regina Deck², Lynn M. Matrisian², Julie Fleshman³, Diane M. Simeone⁷. ¹Virginia
Mason Hospital and Medical Center, Seattle, WA, 2Pancreatic Cancer Action Network, Manhattan Beach, CA, 3University of Texas MD Anderson Cancer Center, Houston, TX, 4Weill Cornell Medicine, New York, NY, 5Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 6University of Pennsylvania, Philadelphia, PA, 7NYU Langone Health, New York, NY.

PO-051  PANNOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma. Vincent J. Picozzi1, Teresa Macarulla2, Philip A. Philip3, Carlos R. Becerra4, Tomislav Dragovich5. 1Virginia Mason Hospital and Medical Center, Seattle, WA, 2Vall d'Hebrón University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain, 3Karmanos Cancer Institute, Detroit, MI, 4Baylor University Medical Center, Dallas, TX, 5Banner MD Anderson Cancer Center, Gilbert, AZ.

PO-052  A pilot study of miRNA expression profile in surgically resected pancreatic ductal adenocarcinoma: initial report from a bi-institutional cohort. Luca Pompella1, Carlo Caputo2, Giuseppe Tirino3, Michela Falco2, Severo Campione4, Sparano Francesca3, Maria Lucia Iacovino3, Chiara Carmen Miceli3, Carlo Molino5, Marco Montella6, Renato Franco6, Gennaro Galizia7, Giovanni Conzo8, Vincenzo Napolitano8, Annamaria Auricchio7, Francesca Cardella7, Fortunato Ciardiello3, Michele Caraglia9, Ferdinando De Vita3. 1Department of Precision Medicine, Division of Medical Oncology, University of Campania "L. Vanvitelli", Aversa, Italy, 2Department of Precision Medicine, Division of Molecular Pathology, University of Campania "Luigi Vanvitelli", Naples, Italy, 3Department of Precision Medicine, Division of Medical Oncology, University of Campania "L. Vanvitelli", Naples, Italy, 4Division of Surgical Pathology, AORN "Antonio Cardarelli", Naples, Italy, 5Division of General Surgery 1, AORN "Antonio Cardarelli", Naples, Italy, 6Division of Surgical Pathology, University of Campania "Luigi Vanvitelli", Naples, Italy, 7Department of Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy, 8Department of Translational medical sciences, University of Campania "Luigi Vanvitelli", Naples, Italy, 9Department of Precision Medicine, Division of Molecular Pathology, University of Campania "L. Vanvitelli", Naples, Italy.

PO-053  Radiosensitization of pancreatic cancer through intracellular gold nanocluster biomineralization. Aaron S. Schwartz-Duval1, Michael P. Kim1, Sunil Krishnan2, Konstantin V. Sokolov1. 1MD Anderson Cancer Center, Houston, TX, 2Mayo Clinic, Jacksonville, FL.

PO-054  A phase II trial of the super-enhancer inhibitor Minnelide in advanced refractory adenosquamous carcinoma of the pancreas (ASCP). Nebojsa Skorupan1, Mehwish I. Ahmad1, Seth M. Steinberg1, Jane B. Trepel1, Derek Criddlebring2, Haiyong Han2, Daniel D. Von Hoff2, Christine Alewine1. 1CCCR, Bethesda, MD, 2Translational Genomics Research Institute, Phoenix, AZ.

PO-055  Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer. Susan Tsai1, Erkut Borazanci2, Margaret Gulley3, Naim Rashid3, Jason Merker3, Abdul H Khan1, Phillip Chisholm1, Bryan Hunt1, Tamara Giorgadze1, William Hall1, Mandana Kamgar1, Douglas B Evans1, Jen Jen Yeh3. 1Medical College of Wisconsin, Milwaukee, WI, 2Honor Health Medical Group, Scottsdale, AZ, 3University of North Carolina,
Chapel Hill, NC.

PO-056  Insulin receptor signaling in pancreatic acinar cells contributes to pancreatic cancer development. Anni M.Y. Zhang, Jenny C.C. Yang, Twan J.J. de Winter, David F. Schaeffer, Janel L. Kopp, James D. Johnson. The University of British Columbia, Vancouver, BC, Canada.

PO-057  Targeting ErbB2 degradation via the ubiquitin–proteasome pathway to inhibit the metastasis of pancreatic cancer. Bo Zhang, Fei Teng, Nengming Lin. Hangzhou First People's Hospital, Hangzhou, China.

Preclinical Models

PO-058  Anti-cancer activity of NTAX-44 (bioprocessed arsenic trioxide) on pancreatic cancer cell line. Yogesh Bendale1, Padma Shastri2, Radha Poojari3, Nandinee Khoi2, Surendra Nagare2, Avinash Kadam2. 1Rasayu Cancer Clinic, Pune, India, 2Rasayani Biologics Pvt. Ltd, Pune, India, 3Innovation Centre, Tata Chemicals Ltd., Pune, India.

PO-059  Epithelial/mesenchymal identity dictates pancreatic cancer cell metastasis. Julienne L. Carstens1, Sujuan Yang1, Pedro Correa de Sampaio1, Xiaofeng Zheng1, Souptik Barua2, Kathleen M. McAndrews1, Arvind Rao3, Jared K. Burks1, Andrew D. Rhim1, Raghu Kalluri1. 1MD Anderson Cancer Center, Houston, TX, 2Rice University, Houston, TX, 3University of Michigan, Ann Arbor, MI.

PO-060  N-terminal RHAMM cooperates with dysfunctional p53 to accelerate the progression of pancreatic cancer. Anthony Lin1, Jennifer Feng1, Xiang Chen1, Dunrui Wang2, Megan Wong1, George Zhang1, Joseph Na1, Tiantian Zhang2, Zhengming Chen1, Yao-Tseng Chen1, Yi-Chieh Nancy Du1. 1Weill Cornell Medicine, New York, NY, 2National Institutes of Health, Bethesda, MD.

PO-061  Myc drives phenotypic heterogeneity, metastasis, and therapy resistance in pancreatic ductal adenocarcinoma. Isabel A. English1, Patrick J. Worth1, Amy T. Farrell1, Brittany L. Allen-Petersen2, Vidhi Shah1, Courtney Betts1, Xiaoyan Wang1, Colin J Daniel1, Mary C. Thoma1, Lisa M. Coussens1, Ellen M. Langer1, Rosalie C. Sears1. 1Oregon Health & Science University, Portland, OR, 2Purdue University, West Lafayette, IN.

PO-062  EUS-guided biopsy of pancreatic mass lesions for the development of patient-derived organoids in Puerto Rico. Andrea S. Flores Pérez1, Janet Mendez Vega1, Ana M. Reyes Ramos1, Carlos Micales2, Madeline Torres-Lugo1, Maribella Domenech1. 1University of Puerto Rico - Mayagüez, Mayagüez, Puerto Rico, 2Hospital Bella Vista, Mayagüez, Puerto Rico.

PO-063  Functional interrogation of immune escape in neoantigen-expressing pancreatic cancer identifies a critical role for the CD155/TIGIT axis. William Freed-Pastor1, Laurens Lambert1, Zackery Ely1, Nimisha Pattada1, Arjun Bhutkar1, Alex Jaeger1, George Eng1, Kim Mercer1, William Hwang1, Tyler Jacks1. 1MIT, Cambridge, MA.
PO-064 ONC212 stimulates cytotoxic T-cell killing, increases tumor-immune cell interactions, and promotes tumor regression in combination with TLY012 in a PDAC murine model. Kelsey E. Huntington1, Anna Louie1, Young Lee1, Jared Mompoint1, Isacco Ferrarini2, Aakash Jhaveri3, Varun V. Prabhu4, Allen Melemed4, Seulki Lee5, Wafik S El-Deiry1. 1Brown University, Providence, RI, 2University of Verona, Verona, Italy, 3Sidney Kimmel Medical College, Philadelphia, PA, 4Chimerix, Durham, NC, 5D&D Pharmatech, Gaithersburg, MD.

PO-065 SIWA318H, an advanced glycation end product (AGE) targeting antibody, is efficacious in a humanized mouse xenograft model for pancreatic cancer. Ashley Jensen1, Gabriela R. Rossi2, Ruben Muñoz1, Kimberly Brothers1, Lewis Gruber2, Misty Gruber2, Haiyong Han1. 1Translational Genomics Research Institute, Phoenix, AZ, 2SIWA Therapeutics, Inc., Chicago, IL.

PO-066 High uptake, retention, and in vivo activity of L-Annamycin in pancreatic cancer models. Ya'an Kang, Rafal Zielinski, Roberto Cardenas Zuniga, Maria Poimenidou, Magdalena Remiszewski, Shaohua Peng, Edd Felix, Krzysztof Grela, Stanislaw Skora, Izabela Fokt, Waldemar Priebe. UT MD Anderson Cancer Center, Houston, TX.

PO-067 A multi-omics study in patient-derived organoids reveals MNX1-HNF1B axis to be indispensable for intraductal mucinous papillary neoplasm lineages. Hiroyuki Kato1, Keisuke Takeda1, Keisuke Yamamoto1, Dousuke Iwadate1, Hiroaki Fujiwara2, Takuma Nakatsuka1, Koji Miyabayashi1, Yotaro Kudo1, Iijichi Hideaki1, Kazuhiko Koike3, Mitsuhiro Fujishiro1. 1Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Division of Gastroenterology, The Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan, 3Department of Gastroenterology, Kanto Central Hospital, Tokyo, Japan.

PO-068 Cholesterol auxotrophy promotes the expansion of centroacinar cells giving rise to the basal subtype of pancreatic adenocarcinoma. Michael Kotliar1, Aizhan Surymbayeva2, Linara Gabitova2, Suraj Peri3, Diana Restifo3, Kathy Q. Cai3, Artem Barski5, Igor Astsaturov2. 1Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2The Marvin & Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Philadelphia, PA, 3Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, PA, 4Histopathology Facility, Fox Chase Cancer Center, Philadelphia, PA, 5Cincinnati Children’s Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, OH.

PO-069 Modeling the tumor microenvironment using tissue engineering technologies. Rodrigo Curvello1, Verena Kast2, Daniela Loesnner1. 1Monash University, Clayton, Australia, 2Max Bergmann Center of Biomaterials Dresden, Dresden, Germany.

PO-070 Longitudinal precision oncology platform to identify chemotherapy-induced vulnerabilities in pancreatic cancer. Katja Peschke1, Hannah Jakubowski1, Arlett Schäfer1, Carlo Maurer1, Sebastian Lange1, Felix Orben1, Raquel Bernd1, Felix Harder1, Matthias Eiber1, Rupert Öllinger1, Melissa Schlitter1, Wilko Weichert1, Veit Phillip1, Christoph Schlag1, Roland
PO-071  Losartan enhances the radiosensitivity of pancreatic ductal adenocarcinoma.  Guoliang Qiao, Yongtao Wang, Sojoodi Mozhdeh, Barrett Cole, Darshini Kuruppu,l Zenan Lin, Lanuti Michael, Kenneth Tanabe, Motaz Qadan. Massachusetts General Hospital, Boston, MA.

PO-072  Inhibiting vasoactive intestinal peptide receptor signaling elicits T cell dependent anti-tumor response of pancreatic ductal adenocarcinoma to immune checkpoint therapy.  Sruthi Ravindranathan1, Passang Tenzin1, Jian Ming Li1, Rohan Dhamsania1, Michael Ware1, Mohammad Zaidi1, Shuhua Wang1, Jingru Zhu1, Maria Cardenas1, Yuan Liu1, Gaurav Joshi1, Sanjeev Gumber1, Brian Robinson1, Anish Sen-Majumdar2, Shanmuganathan Chandrasakam1, Haydn Kissick1, Alan Frey2, Susan Thomas2, Bassel El-Rayes1, Gregory Lesinski1, Edmund K. Waller1. 1Emory University, Atlanta, GA, 2Cambium Oncology, Atlanta, 3Georgia Institute of Technology, Atlanta.

PO-073  Inactivation of Notch4 attenuated pancreatic tumorigenesis in mice.  Kiyoshi Saeki1, Wanglong Qiu1, Richard Friedman1, Carrie Shawber1, Jan Kitajewski2, Jianhua Hu1, Gloria H. Su1. 1Columbia University Irving Medical Center, New York, NY, 2University of Illinois Chicago, Chicago, IL.

PO-074  Identification of C-MET receptor as a therapeutic target in patient-specific tumour models of metastatic pancreatic adenocarcinoma allows identification of a new mode of action for its inhibitors.  Liam Deems, Maria Ivanova, Chery murdered Murphy, Amit Shahar, David Deems, Dmitriy Shvartsman. Cellaria Inc., Wakefield, MA.

PO-075  The elucidation of the role of Prrx1 for acinar to ductal metaplasia in response to acute injury of pancreas in the novel mouse models.  Kensuke Suzuki1, Alina Li1, Jason R. Pitarresi1, Anna M. Chiarella1, Gizem Efe1, Kensuke Sugihara1, Rohit Chandwani2, Anil K. Rustgi1. 1Herbert Irving Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, 2Department of Surgery, Weill-Cornell Medical School, New York, NY.


PO-077  Establishment of a novel living biobank of patient-derived pancreatic cancer organoids with genomic and drug response characterization.  Irene Y. Xie1, Laura Tamblyn2, Karen Ng2, Eugenia Flores-Figueroa2, Julie M. Wilson3, Gun Ho Jang3, Amy X. Zhang3, Stephanie Ramotar2, Anna Dodd2, Nikola Radulovich2, Jennifer J. Knox2, Grainne M. O’Kane2, Steven Gallinger2, Faiyaz Notta2. 1University of Toronto, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada, 3Ontario Institute of Cancer Research,
PO-078  Identification of new drivers in PDAC early progression using engineered human primary pancreatic cells. Yi Xu\textsuperscript{1}, Jun Liu\textsuperscript{1}, Michael Hunter Nipper\textsuperscript{1}, Han Xu\textsuperscript{2}, Pei Wang\textsuperscript{1}. \textsuperscript{1}The University of Texas Health San Antonio, San Antonio, TX, \textsuperscript{2}MD Anderson Cancer Center, Smithville, TX.

PO-079  Proteomic profiling reveals subtype specific kinase expression in pancreatic cancer. Yi Xu, Michael East, Ashley Morrison, Gabriela Herrera, Laura Peng, Gary Johnson, Jen Jen Yeh. UNC Chapel Hill, Chapel Hill, NC.


Signaling

PO-081  Studying MYC's contribution to replication stress at the nuclear pore. Gabriel M. Cohn, Colin J. Daniel, Daniel F. Liefwalker, Rosalie C. Sears. Oregon Health & Science University, Portland, OR.

PO-082  Delineating the molecular basis of early dissemination of pancreatic cancer. Taelor Ekstrom\textsuperscript{1}, Dmytro Grygoryev\textsuperscript{1}, Terry Morgan\textsuperscript{2}, Kenneth S Zaret\textsuperscript{3}, Jungsun Kim\textsuperscript{4}. \textsuperscript{1}Cancer Early Detection Advanced Research Center, Oregon Health & Science University, Portland, OR, \textsuperscript{2}Cancer Early Detection Advanced Research Center, Department of Pathology, Knight Cancer Institute (Cancer Biology Research Program), Oregon Health & Science University School of Medicine, Portland, OR, \textsuperscript{3}Institute for Regenerative Medicine, Department of Cell and Developmental Biology, Abramson Cancer Center (Tumor Biology Program), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, \textsuperscript{4}Cancer Early Detection Advanced Research Center, Department of Molecular and Medical Genetics, Knight Cancer Institute (Cancer Biology Research Program), Oregon Health & Science University School of Medicine, Portland, OR.

PO-083  Rac1 is required for the maintenance of Kras\textsuperscript{G12D}-driven pancreatic ductal adenocarcinoma. Adrien Grimont\textsuperscript{4}, John Nguyen\textsuperscript{1}, John Erby Wilkinson\textsuperscript{2}, Paul Zumbo\textsuperscript{1}, Laura Martin\textsuperscript{1}, Steven D. Leach\textsuperscript{1}, Rohit Chandwani\textsuperscript{1}. \textsuperscript{1}Weill Cornell Medicine, New York, NY, \textsuperscript{2}University of Michigan Medical School, Michigan, NY.

PO-084  The role of p53 in the development of pancreatic ductal adenocarcinoma. Kathryn J. Hanson, Brittany M. Flowers, Nicholas Hughes, Hannes Vogel, Le Cong, Laura D. Attardi. Stanford University, Stanford, CA.

PO-085  Identification of the nucleotide-free state as a therapeutic vulnerability for
mutant selective inhibition of RAS. Imran Khan\textsuperscript{1}, Akiko Koide\textsuperscript{2}, Mariyam Zuberi\textsuperscript{1}, Gayatri Ketavarapu\textsuperscript{2}, Eric Denbaum\textsuperscript{2}, Kai Wen Teng\textsuperscript{2}, Matthew Rhet\textsuperscript{1}, Russell Spencer Smith\textsuperscript{3}, G. Aaron Hobbs\textsuperscript{1}, Ernest Ramsay Camp\textsuperscript{1}, Shohei Koide\textsuperscript{2}, John P. O’ Bryan\textsuperscript{1}. \textsuperscript{1}Medical University of South Carolina, Charleston, SC, \textsuperscript{2}New York University, New York, NY, \textsuperscript{3}University of Illinois Chicago, Chicago, IL.


PO-087 SCAP-SREBP signaling is essential for acinar cell differentiation and maintenance, and pancreatic morphogenesis, influencing resident pools of cancer-forming progenitor cells. Anna C. Lilly, Aizhan Surumbayeva, Erica A Golemis, Igor Astsaturov. Fox Chase Cancer Center, Philadelphia, PA.

PO-088 Classification based on efficiency of mRNA translation reveals a metabolically-dependent subtype of pancreatic cancer. Sauyeun Shin\textsuperscript{1}, Remy Nicolle\textsuperscript{2}, Mehdi Liauzun\textsuperscript{1}, Jacobo Solorzano\textsuperscript{1}, Alexia Brunel\textsuperscript{1}, Christine Jean\textsuperscript{1}, Remi Samain\textsuperscript{1}, Jérôme Raffenne\textsuperscript{1}, Cindy Neuzillet\textsuperscript{3}, Carine Joffre\textsuperscript{4}, Stephane Rocci\textsuperscript{5}, Juan Iovanna\textsuperscript{6}, Nelson Dusetti\textsuperscript{6}, Ola Larsson\textsuperscript{7}, Stephane Pyronnet\textsuperscript{1}, Corinne Bousquet\textsuperscript{1}, Yvan Martineau\textsuperscript{1}. \textsuperscript{1}CRCT, Inserm U1037, Toulouse, France, \textsuperscript{2}CIT, Ligue Nationale Contre Le Cancer, Paris, France, \textsuperscript{3}Medical Oncology Department, Curie Institute, Saint Cloud, France, \textsuperscript{4}CRCT Inserm U1037, Toulouse, France, \textsuperscript{5}C3M, Inserm U1065, Nice, France, \textsuperscript{6}CRCM, Inserm, Marseille, France, \textsuperscript{7}Karolinska Institutet, Stockholm, Sweden.

PO-089 Identification of a LAMC2-regulated network featuring targetable effectors for dual therapies in pancreatic cancer. Shruthi Narayanan\textsuperscript{1}, Oihane Erice\textsuperscript{2}, Iker Feliu\textsuperscript{2}, Caterina Vicentini\textsuperscript{3}, Rodrigo Entrialgo-Cadierno\textsuperscript{2}, Karmele Valencia\textsuperscript{2}, Elisabet Guruceaga\textsuperscript{4}, Purvesh Khatri\textsuperscript{5}, Vicenzo Corbo\textsuperscript{3}, Silvestre Vicent Cambra\textsuperscript{6}, Mariano Ponz-Sarvise\textsuperscript{1}. \textsuperscript{1}Clinica Universidad de Navarra, Medical Oncology Department, Pamplona, Spain, \textsuperscript{2}University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain, \textsuperscript{3}Department of Diagnostics and Public Health, University of Verona, Verona, Italy, \textsuperscript{4}University of Navarra, Center for Applied Medical Research, Computational Biology Program, Pamplona, Spain, \textsuperscript{5}Stanford University, Stanford, CA, \textsuperscript{6}University of Navarra, Center for Applied Medical Research, Program in Solid Tumors and Department of Pathology, Anatomy and Physiology; IdiSNA, Navarra Institute for Health Research; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain, Pamplona, Spain.

PO-090 TGF-β induced EMT gene expression is associated with promoter demethylation in pancreatic cancer. Manjul Rana\textsuperscript{1}, Abul Elahi\textsuperscript{1}, Abidemi O. Ajidahun\textsuperscript{1}, Rita G. Kansal\textsuperscript{1}, Anders E. Berglund\textsuperscript{2}, David Shibata\textsuperscript{1}, Evan S. Glazer\textsuperscript{1}. \textsuperscript{1}UTHSC, Memphis, TN, \textsuperscript{2}Moffitt Cancer Center, Tampa, FL.

PO-091 Histamine receptor 1 (HRH1): A potentially novel G protein-coupled receptor (GPCR) therapeutic target in pancreatic adenocarcinoma (PDAC) cells and tumors. Cristina Salmeron, Krishna Sriram, Mehrak Javadi-Paydar, Paul A. Insel. \textsuperscript{1}UCSD, La Jolla, CA.
PO-092 Influence of the IL-13-receptor alpha 1 chain on the malignant phenotype of pancreatic cancer cells. Jingwei Shi, Marko Kornmann, Benno Traub. University of Ulm, Ulm, Germany.

PO-093 JNK2 suppresses the growth and invasion of pancreatic cancer and is opposed by JNK1. Jingwei Shi, Xiaodong Tian, Marko Kornmann, Benno Traub. University of Ulm, Ulm, Germany.

PO-094 Ga13 loss in KPC mouse model promotes well-differentiated pancreatic tumors that are susceptible to mTOR inhibition. Mario A. Shields, Christina Spaulding, Mahmoud G. Khalafalla, Thao N. D. Pham, Hidayatullah G. Munshi. Northwestern University, Chicago, IL.

Tumor Microenvironment

PO-095 A cancer cell-intrinsic GOT2-PPARδ axis suppresses antitumor immunity. Jaime Abrego1, Hannah Sanford-Crane1, Chet Oon1, Xu Xiao2, Courtney Betts3, Duanchen Sun3, Shanthi Nagarajan4, Zheng Xia3, Lisa Coussens1, Peter Tontonoz5, Mara Sherman1. 1Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, 2Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 3Computational Biology Program, Oregon Health & Science University, Portland, OR, 4Medicinal Chemistry Core, Oregon Health & Science University, Portland, OR, 5Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.

PO-096 The synaptic protein Netrin G1 ligand (NGL-1) modulates tumorigenesis and immunosuppression in pancreatic cancer. Debora Barbosa Vendramini Costa1, Ralph Francescone1, Janusz Franco-Barraza1, Tiffany Luong1, Nina Steele2, Benjamin Allen2, Marina Pasca di Magliano3, Charline Ogier1, Igor Astsaturov1, Kathy Q Cai1, Andres J Klein-Szanto1, Huamin Wang4, Kerry Campbell1, Edna Cukierman1. 1Fox Chase Cancer Center, Philadelphia, PA, 2Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI, 3Department of Surgery, University of Michigan, Ann Arbor, MI, 4Department of Anatomical Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

PO-097 Addition of losartan to FOLFORINOX and chemoradiation reduces the expression of pro-invasive and immunosuppressive genes in locally-advanced pancreatic cancer. Yves Boucher1, Jessica M. Posada2, Sonu Subudhi2, Ashwin S. Kumar2, Ivy X. Chen2, Mei R. Ng2, Mari Mino-Kenudson3, Nilesk Talele2, Dan G. Duda2, Dai Fukumura3, Janet E. Murphy3, Jeffrey W. Clark3, David P. Ryan3, Carlos Fernandez-Del Castillo3, Theodore S. Hong3, Rakesh K. Jain3. 1Massachusetts General Hospital and Harvard Medical School, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Harvard Medical School, Boston, MA.
PO-098  Longitudinal profiling of pancreatic cancer patients identifies Interleukin-8 as a mediator of myeloid-epithelial crosstalk. Eileen S. Carpenter1, Samantha Kemp2, Padma Kadiyala1, Nina Steele1, Ahmed Elhossiny1, Stephanie The1, Valerie Gunchick1, Michelle Anderson1, Wenting Du1, Carlos Espinoza1, Richard Kwon1, Erik-Jan Wamsteker1, Anoop Prabhu1, Allison Schulman1, Vaibhav Sahai1, Timothy Frankel1, Filip Bednar1, Marina Pasca di Magliano1. 1University of Michigan, Ann Arbor, MI, 2University of Pennsylvania, Philadelphia, PA.

PO-099  The immunogenic and therapeutic implications of cancer cell-mediated CD73 activity and extracellular adenosine signaling promote an immunosuppressive microenvironment in pancreatic cancer. Anna M. Chiarella1, Jason R. Pitaressi2, Kensuke Suzuki1, Alina Li1, Ting Chen1, Benjamin Izar1, Catherine S. Spina1, Gulam A. Manji1, Gizem Efe1. 1Columbia University Irving Medical Center, New York City, NY, 2University of Pennsylvania, Philadelphia, PA.

PO-100  Lorazepam promotes desmoplasia and ischemic necrosis in murine pancreatic ductal adenocarcinoma. Abigail C. Cornwall, Abdulrahman A. Alahmari, Arwen A. Tisdale, Kathryn Maraszek, Swati Venkat, Michael E. Feigin. Roswell Park Comprehensive Cancer Center, Buffalo, NY.

PO-101  Characterization of longitudinally collected fine needle aspiration biopsies of pancreatic ductal adenocarcinoma upon endoscopic ultrasound guided radiofrequency ablation. Krisha Desai1, Patrick Varun Lawrence1, Christopher Wadsworth2, Nagina Mangal2, Nagy Habib2, Anguraj Sadanandam1, Mikael Sodergren2. 1Institute of Cancer Research, London, United Kingdom, 2Imperial College, London, United Kingdom.

PO-102  Fibroblast-derived interleukin-33 promotes pancreatic ductal adenocarcinoma as a result of tumor cell KRASG12D. Katelyn Donahue, Wenting Du, Carlos Espinoza, Eileen Carpenter, Kristee Brown, Nina Steele, Marina Pasca di Magliano. University of Michigan, Ann Arbor, MI.

PO-103  Cellular origin influences immune microenvironment in a pancreatic cancer mouse model with loss of Pten and activation of Kras. Yan Dou1, Wesley Hunt1, Justin Chhuor1, Farnaz Taghizadeh1, Atefeh Samani1, Karnjit Sarai1, Claire Dubois2, David F. Schaeffer1, Maïke Sander2, Janel L. Kopp1. 1University of British Columbia, Vancouver, BC, Canada, 2University of California-San Diego, La Jolla, CA.

PO-104  Activation of WNT signaling in CD4+ T cells promotes immune suppression in pancreatic cancer. Wenting Du, Rosa E. Menjivar, Katelyn Donahue, Ashley Velez-Delgado, Marina Pasca di Magliano. University of Michigan, Ann Arbor, MI.

PO-105  Overcoming stromal barriers in PDA with a novel polymeric Toll-like receptor agonist. Christopher C. DuFort1, Ciana L. Lopez2, Martin C. Whittle1, Vladimir Vlaskin2, Aditi Vadodkar1, Selvi Srinivasan2, Patrick S. Stayton2, Sunil R. Hingorani1. 1Fred Hutchinson Cancer Research Center, Seattle, WA, 2University of Washington, Seattle, WA.

PO-107  Fibroblast differentiation trajectories elicit regional tissue states in pancreatic cancer. Barbara T. Grünwald, Curtis McCloskey, Antoine Devisme, Foram Vyas, Geoffroy Andrieux, Kazeera Aliar, Faiyaz Notta, Grainne O’Kane, Julie Wilson, Jennifer Knox, Sandra Fischer, Thomas Kirsch, Melanie Boerries, Steven Gallinger, Rama Khokha. 1Princess Margaret Cancer Centre, Toronto, ON, Canada, 2University of Freiburg, Freiburg, Germany, 3Ontario Institute for Cancer Research, Toronto, ON, Canada, 4University Health Network, Toronto, ON, Canada, 5Princess Margaret Cancer Centre, Toronto, Canada.

PO-108  Evaluation of antitumor activity of modified-gemcitabine solid-lipid nanoparticle in pancreatic pdx models. Edward Agyare, Taylor Smith, Andriana Inkoom, Bo Han, Jose Trevino, Nkafu Bechem Ndemazie. 1College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, 2Food and Drug Administration, Silver Spring, MD, 3Keck School of Medicine, University of Southern California, Los Angeles, CA, 4Department of Surgery, College of Medicine, Virginia Commonwealth University, Richmond, VA.

PO-109  Dynamic regulation of the expression of KRAS and its effectors determines the ability of pancreatic acinar cells to initiate tumorigenesis. Patrick Jacquemin, Mohamad Assi. University of Louvain, Brussels, Belgium.

PO-110  Targeting Cathepsin B in the pancreatic stellate cells stimulates CD8+ T cell dependent anti-tumor immune response. Bharti Garg, Tejeshwar Jain, Utpreksha Vaish, Vikas Dudeja. University of Alabama at Birmingham, birmingham, AL.

PO-111  A Human Single-cell RNA Sequencing Atlas of Pancreatic Ductal Adenocarcinoma Enables Harmonized Cell Type Calling and Comprehensive Analyses of Potential Intercellular Signaling. Benedict Kinny-Köster, Melissa R. Lyman, Dimitrios N. Sidiropoulos, Melanie Loth, Alexandra B. Puscek, Laura D. Wood, Jin He, Jun Yu, Richard A. Burkhart, Elizabeth M. Jaffee, Jacquelyn W. Zimmerman, Elana J. Fertig. 1Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, 2Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 3Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD.

PO-112  Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade. Varintra E. Lander, Jad I. Belle, Brett L. Knolhoff, John M. Herndon, Cedric Mpoy, Buck E. Rogers, Julie K. Schwarz, David G. DeNardo. Washington University in St. Louis, St. Louis, MO.
PO-113  The prolyl isomerase PIN1 plays a critical role in fibroblast differentiation states to support pancreatic cancer. Ellen M. Langer, Isabel A English, Vidhi Shah, Kevin MacPherson, Kayleigh M. Kresse, Brittany L. Allen-Petersen, Colin J. Daniel, Mara H. Sherman, Andrew Adey, Rosalie C. Sears. 1Oregon Health & Science University, Portland, OR, 2Purdue University, West Lafayette, IN.

PO-114  STAT3 in cancer-associated fibroblasts promotes an immunosuppressive tumor microenvironment. Julia E. Lefler, Michael Ostrowski, Catherine MarElia-Bennett. Medical University of South Carolina (MUSC), Charleston, SC.

PO-115  Effects of mesothelin exert on tumor microenvironment in pancreatic ductal adenocarcinoma. Dongliang Liu, Ethan Poteet, Zhengdong Liang, Emily Laplante, Lisa Brubaker, Sadhna Dzingra, Aleksandar Milosavljevic, Changyi Chen, Qizhi Cathy Yao. Baylor College of Medicine, Houston, TX.

PO-116  Deletion of Arginase 1 in myeloid cells alters the pancreatic cancer microenvironment. Rosa E. Menjivar, Zenib Nwosu, Wenting Du, Katelyn Donahue, Carlos Espinoza, Ashley Velez-Delgado, Kristee Brown, Wei Yan, Christopher Halbrook, Yaqing Zhang, Costas Lyssiotis, Marina Pasca di Magliano. 1University of Michigan, Ann Arbor, MI, 2University of California Irvine, Irvine, CA.

PO-117  The role of Hippo signaling in stromal-epithelial interactions in acinar-to-ductal metaplasia and pancreatic cancer initiation. Julia Messina-Pacheco, Yasser Riazalhosseini, Zu-hua Gao, Alex Gregorieff. 1Department of Pathology, McGill University and the Research Institute of McGill University Health Centre, Montreal, QC, Canada, 2Department of Human Genetics, McGill University and the McGill University and Genome Quebec Innovation Centre, Montreal, QC, Canada.

PO-118  The tumor immune microenvironment is decisive in the survival of pancreatic ductal adenocarcinoma. Hosein M. Aziz, Lawlaw Saida, Willem de Koning, Andrew Stubbs, Yunlei Li, Casper H. J. van Eijck, Dana A. M. Mustafa. Erasmus University Medical Center, Rotterdam, Netherlands.

PO-119  DFMO mediated improvement in survival of an orthotopic model of pancreatic cancer is associated with modulating immune suppression in the tumor microenvironment. Sai Preethi Nakkina, Sarah B. Gitto, Veethika Pandey, Jordan M. Beardsley, Michael W. Rohr, Jignesh G. Parikh, Otto Phanstiel, Deborah A. Altomare. 1University of Central Florida, Orlando, FL, 2University of Pennsylvania, Philadelphia, PA, 3Orlando VA Medical Center, Orlando, FL, 4College of Medicine, University of Central Florida, Orlando, FL.

Investigating the role of human cancer-associated fibroblasts in pancreatic cancer invasion using patient-derived PDAC organoids. Bernat Navarro-Serer, Kenna Sherman, Laura D. Wood. Johns Hopkins University School of Medicine, Baltimore, MD.

Combined CDK and BET inhibition reprograms the tumor and stromal compartments to enhance anti-tumor immunity in immunologically-cold CDKN2A-deficient pancreatic cancer. Brian M. Olson, Alison J. Thomas, Michael B. Ware, Gregory B. Lesinski. Emory University, Atlanta, GA.

Development of a 3D Biomimetic Metastatic Liver Niche Model for Pancreatic Cancer. Mahsa Pahlavan, Wei Kun Xiao, Flora Eun, Chang-Il Hwang, Reginald Hill. 1Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, 2Lawrence J. Ellison Institute for Transformative Medicine of USC, University of Southern California, Los Angeles, CA, 3Department of Microbiology and Molecular Genetics, College of Biological Sciences, University of California Davis, Davis, CA.


The role of KDM6A in pancreatic cancer immune microenvironment. Lin Jin, Jing Yang, Zhu Jun Yi, Hong S Kim, Jiaqi Shi. University of Michigan, Ann Arbor, MI.

Loss of HIF1A decreases resistance to radiation and invasiveness in pancreatic ductal adenocarcinoma. Kevin J. Tu, Sanjit K. Roy, Binny Bhandary, Amit Sawant, Hem D. Shukla. 1University of Maryland School of Medicine, Baltimore, MD, 2University of Maryland, Baltimore, MD.

A uPA/uPAR axis in both the tumor cell and stromal compartment drives PDAC disease progression. Yi Yang, Sara R. Abrahams, Aditi Kothari, Harshi Matada, Keely Davey, Alisa S. Wolberg, Matthew J. Flick. University of North Carolina, Chapel Hill, Chapel Hill, NC.

Epigenetic and transcriptional control of the epidermal growth factor receptor (EGFR) regulates the tumor immune microenvironment in pancreatic cancer. Salina Yuan, Jinyang Li, Ben Stanger, Robert Norgard, Fangxue Yan, Il-Kyu Kim, Allyson Merrell, Yoge Sela, Yanqing Jiang, Natarajan V. Bhanu, Ben A. Garcia, Robert H. Vonderheide.

PO-130  Macropinocytosis at the nexus of crosstalk in the pancreatic tumor microenvironment. Yijuan Zhang1, M. Victoria Recouvreux1, Michael Jung1, Koen Galencamp1, Yunbo Li2, Olga Zagnitko1, David Scott1, Andrew Lowy2, Cosimo Commisso1. 1Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 2University of California San Diego, La Jolla, CA.

PO-131  The role of liver endothelium on pancreatic cancer growth. Wei Zhang1, Michel’le Wright1, Moeez Rathore1, Ali Vaziri-Gohar1, Jordan Winter2, Rui Wang2. 1Case Western Reserve University, Cleveland, OH, 2Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH.